((自动化翻译由路透提供，请见免责声明 ))
11月19日 - ** 制药商Incyte公司 股价盘前下跌11.7%至68美元
** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 (link)。
** INCY还表示，另一种治疗严重瘙痒症（胆汁淤积性瘙痒症）的实验性药物的中期试验数据不支持进一步开发。
** 26家券商中有12家对该股的评级为 "买入 "或更高，13家为 "持有"，1家为 "卖出"；其PT中值为75.06美元--LSEG数据
** 截至上次收盘，该股今年累计上涨 22.6%，而道琼斯美国医疗保健指数 的涨幅为 3.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.